Published in Cancer Weekly, May 29th, 2007
Long gone are the days when a drug successfully completing Phase III trials was virtually assured of launch.
The results of late-stage clinical trials are scrutinised as never before, and even products that surmount safety and efficacy requirements must overcome increasingly challenging pharmacoeconomic and medical outcome hurdles.
The high cost of new cancer therapies has made them targets for critical analysis. The rewards may be great for patients and companies alike, but...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.